Evidence map›Paper›PMID 42410272›Full record

Observational studyAnnals of hematology2026

Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective study.

Taichiro Tokura, Satoshi Wakita, Keiko Fukunaga, Yasunobu Nagata, Shunsuke Yui, Atsushi Marumo, Tomoaki Kitano, Mayumi Yogosawa, Daisuke Minakata, Shinichi Kako and 29 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Taichiro TokuraDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. t-tokura@nms.ac.jp.
Satoshi WakitaDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. aaa11140@nms.ac.jp.
Keiko FukunagaDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Yasunobu NagataDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Shunsuke YuiDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Atsushi MarumoDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Tomoaki KitanoDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Mayumi YogosawaDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Daisuke MinakataDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Sho OkamotoDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Taku TsukamotoDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Junya KandaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Atsushi SatakeFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Haruko TashiroDepartment of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan.
Masao OgataDepartment of Hematology, Oita University Hospital, Oita, Japan.
Kuniko TakanoDepartment of Hematology, Oita University Hospital, Oita, Japan.
Jun AndoDivision of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Taro EdahiroDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yuri KamitsujiDepartment of Hematology, Panasonic Health Insurance Organization Matsushita Memorial Hospital, Osaka, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Eri KawataDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Keiichi MoriyaDepartment of Hematology, IMS Group Shinmatsudo Central General Hospital, Chiba, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Kazutaka NakayamaDepartment of Hematology, Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan.
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Katsuhiro ShonoDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
Shinichiro MoriHematology Department, St. Luke's International Hospital, Tokyo, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Akiko HashimotoDepartment of Immunology and Hematology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Hideharu MutoDivision of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Daichi NishiyamaDepartment of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Japan.
Sayuri MotomuraDepartment of Hematology, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The KMT2A gene is frequently altered in acute myeloid leukemia (AML). KMT2A abnormalities include partial tandem duplication (PTD), single-nucleotide variants (SNVs), and chromosomal rearrangements such as t(9;11)(p21.3;q23.3) and t(v;11q23.3). However, with the widespread adoption of next-generation sequencing (NGS), PTD has been assessed less frequently. We evaluated the clinical features and prognostic impact of PTD and other KMT2A abnormalities. We analyzed the KMT2A abnormalities and coexisting genetic alterations in 585 patients with de novo AML diagnosed across 25 institutions (1991-2020). Using bone marrow and/or peripheral blood samples, we identified PTD by targeted polymerase chain reaction-based assay, chromosomal rearrangements by karyotyping, and SNVs and other genetic alterations by targeted NGS. KMT2A abnormalities were detected in 18.3% of de novo AML, comprising PTD in 6.7%, SNVs in 5.1%, t(9;11)(p21.3;q23.3) in 2.2%, and t(v;11q23.3) in 4.8%; 0.5% had concurrent KMT2A abnormalities. Patients with PTD, t(9;11)(p21.3;q23.3), or t(v;11q23.3) had significantly shorter relapse-free survival (RFS) than the KMT2A wild-type group (hazard ratio [HR] 1.99, p = 0.048; HR 3.13, p = 0.009; HR 2.41, p = 0.006, respectively). Patients with PTD, t(9;11)(p21.3;q23.3), or t(v;11q23.3) had significantly shorter overall survival (OS) than the KMT2A wild-type group (HR 3.92, p < 0.001; HR 4.58, p < 0.001; HR 3.73, p < 0.001, respectively). Within the PTD group, older age (p = 0.030) and higher lactate dehydrogenase (p = 0.005) remained independent adverse prognostic factors. KMT2A-PTD is associated with inferior RFS and OS in de novo AML. Our findings support routine PTD testing at diagnosis and the incorporation of KMT2A-PTD into prognostic risk stratification and clinical decision-making.

Indexed as

Gene DuplicationHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinTandem Repeat SequencesAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinAcute myeloid leukemia (AML)KMT2AMLLPartial tandem duplication (PTD)Prognostic factorsRisk stratification

Identifiers

PMID42410272
PMCPMC13619693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.